Oligometastatic Esophageal Cancer Treatment Timing Study, 142 Patients

A multicenter retrospective study reviewed 142 patients with oligometastatic esophageal squamous cell carcinoma who received first-line radiotherapy and chemoimmunotherapy between 2019 and 2024. The dataset likely contains patient records categorized by treatment timing groups and analyzed for survival outcomes and adverse events. It was authored by Tian Xu and shared on figshare under a CC-BY-4.0 license.

Use Cases

• Compare overall survival outcomes based on radiotherapy timing relative to chemoimmunotherapy.
• Analyze prognostic factors for oligometastatic esophageal squamous cell carcinoma.
• Evaluate the incidence of Grade ≥ 3 treatment-related adverse events across different treatment strategies.
• Model progression-free survival using patient treatment timing groups.

Strengths

• Includes 142 patient records from a multicenter study.
• Data spans a 5-year period from 2019 to 2024.
• Analysis employs Inverse Probability of Treatment Weighting (IPTW) and multivariable Cox regression to mitigate confounding.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (55.5 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Multicenter retrospective review of patient records.

Time Range

2019 to 2024

Freshness

Last updated 2026-05-18 04:10:41; freshness should be verified.